Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (151-160 of 232) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|February 21, 2020
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasmRaffaele Palmieri, Sarah A Buckley, Megan Othus, et al.
Leukemia|February 17, 2022
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasmAnna B Halpern, Megan Othus, Genevieve Alcorn, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic NeoplasiaSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood|August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportFabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapyHale B Caglar, Roy B Tishler, Megan Othus, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Pageof 24

Showing results (151-160 of 232) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|February 21, 2020
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasmRaffaele Palmieri, Sarah A Buckley, Megan Othus, et al.
Leukemia|February 17, 2022
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasmAnna B Halpern, Megan Othus, Genevieve Alcorn, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic NeoplasiaSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood|August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportFabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapyHale B Caglar, Roy B Tishler, Megan Othus, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Pageof 24